More tools:Markets·Screener·Research·Chat

AEON Biopharma, Inc. (AEON) Financial Statements

AEON Biopharma, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Z17HFQ5
XASE · usd
0.24▼ 0.01 (-2.41%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close0.24
Day's Range0.23 – 0.25
52-Week Range0.18 – 1.45
Volume154.4K
Avg Volume3.0M
Share Statistics
Shares Outstanding
Employees8
ExchangeXASE
Listed2023-07-24
Share count as of August 6, 2026
Loading Income Statement…
Key questions about AEON Biopharma, Inc. (AEON)
What is AEON Biopharma, Inc.'s Market Cap?
AEON Biopharma, Inc.'s Market Cap is $11.7M, based on as-reported figures from SEC (XBRL) filings.
What is AEON Biopharma, Inc.'s Enterprise Value?
AEON Biopharma, Inc.'s Enterprise Value is $8.3M, based on as-reported figures from SEC (XBRL) filings.
What is AEON Biopharma, Inc.'s EV / EBITDA?
AEON Biopharma, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is AEON Biopharma, Inc.'s Net Income (TTM)?
AEON Biopharma, Inc.'s Net Income (TTM) is -$54.6M, based on as-reported figures from SEC (XBRL) filings.
What is AEON Biopharma, Inc.'s EBITDA?
AEON Biopharma, Inc.'s EBITDA is -$19.8M, based on as-reported figures from SEC (XBRL) filings.
What is AEON Biopharma, Inc.'s Diluted EPS (TTM)?
AEON Biopharma, Inc.'s Diluted EPS (TTM) is -1.10, based on as-reported figures from SEC (XBRL) filings.
What is AEON Biopharma, Inc.'s Net Debt?
AEON Biopharma, Inc.'s Net Debt is -$3.4M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jul 21, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Selling, general and administrative
Research and development
Change in fair value of contingent consideration
Total operating costs and expenses
Loss from operations
Other (loss) income:
Change in fair value of convertible notes
Change in fair value of warrants
Loss on issuance of warrants——
Loss on extinguishment of debt——
Loss on derivative liability——
Other income, net
Total other (loss) income, net
(Loss) income before taxes
Net (loss) income
Basic net (loss) income per share (in dollars per share)
Diluted net (loss) income per share (in dollars per share)